Cannabis Bioscience International Holdings Reports Near-Zero Cash, Worsening Financials, and Ineffective Controls Amidst Going Concern Warning

summarizeSummary

Cannabis Bioscience International Holdings, Inc. reported critically low cash, worsening financial metrics, and ineffective disclosure controls, reaffirming substantial doubt about its ability to continue as a going concern.

check_boxKey Events

• Going Concern Warning Reaffirmed

  The company continues to raise substantial doubt about its ability to continue as a going concern, citing recurring losses, negative working capital, and negative cash flows from operations.

• Critically Low Cash Position

  Cash and cash equivalents plummeted to $90 as of February 28, 2026, down from $12,952 nine months prior, indicating severe liquidity issues.

• Ineffective Disclosure Controls

  Management concluded that the company's disclosure controls and procedures were not effective as of February 28, 2026.

• Worsening Financials and Increased Debt

  The working capital deficit increased to $1,217,630 from $916,878, and related-party payables rose significantly to $845,294 from $623,474, highlighting deteriorating financial health and increasing reliance on related-party financing.

auto_awesomeAnalysis

This quarterly report paints a dire picture of Cannabis Bioscience International Holdings' financial health. The company's cash reserves have dwindled to a critically low $90, exacerbating its existing going concern warning. The significant decline in revenue, coupled with a worsening working capital deficit and increasing related-party debt, indicates severe liquidity and operational challenges. Furthermore, the disclosure of ineffective disclosure controls raises serious concerns about the reliability of financial reporting and overall corporate governance. The extreme customer concentration, with one customer accounting for 99% of revenue, adds another layer of substantial business risk. Investors should view these developments as highly negative, reinforcing the significant doubt about the company's ability to continue operations.